SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01050400

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk

The purpose of this study is to determine if non-invasive salivary genetic screening of breastfeeding mothers taking codeine will allow for the successful identification of mother-infant pairs susceptible to adverse events and to prevent these adverse events by personalizing their medication to their genetics.

NCT01050400 Cytochrome P450 2D6 Ultra-rapid Metabolism
MeSH: Drug-Related Side Effects and Adverse Reactions

1 Interventions

Name: Cytochrome P450 2D6 (CYP2D6) genetic screening.

Description: Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.

Type: Genetic

Observant Prospective CYP2D6 genetic screening


Primary Outcomes

Measure: Incidence of maternal and neonatal CNS depression in the prospective pharmacogenetic screening group to that of a retrospectively screened population

Time: 5-8 days post c-section surgery

Secondary Outcomes

Measure: Incidence of the phase II uridine diphosphate glucuronyltransferase 2B7 (UGT2B7)*2/*2 variant which has been associated with higher morphine 6-glucuronide to morphine ratios.

Time: Minimum 1 week prior to c-section

Measure: Incidence of the C3435T polymorphism in the multi-drug resistance gene (MDR1) which has been associated with significantly greater pain relief from morphine treatment.

Time: Minimum 1 week prior to c-section

Measure: Incidence of the A118G polymorphism in the opioid receptor 1 (OPRM1) which has been associated with reduced response to morphine treatment.

Time: Minimum 1 week prior to c-section

Time Perspective: Prospective

Other


There are 2 SNPs

SNPs


1 A118G

Incidence of the A118G polymorphism in the opioid receptor 1 (OPRM1) which has been associated with reduced response to morphine treatment.. null. --- A118G ---


2 C3435T

Incidence of the C3435T polymorphism in the multi-drug resistance gene (MDR1) which has been associated with significantly greater pain relief from morphine treatment.. null. --- C3435T ---



HPO Nodes